News – Page 116 – Endpoints News

Exclusive: Biotech investor Sofinnova hires former Biogen medical chief

9 months ago

BioMarin scales back launch for hemophilia gene therapy, pitches path to profitability

9 months ago

Eliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease

9 months ago

Nuvation pauses BET inhibitor plans after checking out interim Phase 1 data

9 months ago

Mallinckrodt sells photopheresis platform Therakos for $925M

9 months ago

Bristol Myers to cut more jobs at headquarters as part of announced restructure

9 months ago

Q&A: Genentech's new CEO on AI, IRA and radiopharma

9 months ago

Third Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific out of China

9 months ago

What the meltdown in the stock market means for biotech and pharma

9 months ago

Layoffs at Sumitomo; Galderma and L’Oréal strike a deal

9 months ago

MBX Biosciences rakes in $63.5M for peptide therapies

9 months ago

FDA wants new trial of Actinium’s radioactive iodine drug, company to seek partner

9 months ago

Florida CNS gene therapy biotech shuts down

9 months ago

Bayer plans label expansion for Kerendia after Phase 3 win in heart failure

9 months ago

BioNTech says no to Phase 3 with Genmab’s bispecific antibody

9 months ago

Bristol Myers returns TIGIT bispecific to Agenus, frees itself from $1B+ milestones

9 months ago

Eisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday; What’s next for MDMA?; and more

9 months ago

Advisory committee votes in favor of Zevra Therapeutics' rare genetic disease drug

9 months ago

Doses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA supply list

9 months ago

Massachusetts' plan for $1B in life science investment stalls in state legislature

9 months ago

Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical study

9 months ago

Exclusive: Devoted Health raises $112M, plots insurance markets expansion

9 months ago

In Japan, sales of Eisai and Biogen's Alzheimer's drug begin to accelerate

9 months ago

Apogee and Spyre founder launches another autoimmune biotech, and it's got $80M to start

9 months ago

First page Previous page 113 114 115116117 118 119 Next page Last page